 FREMONT, CA, Aug. 26, 2021 GLOBE NEWSWIRE -- via NewMediaWire ABVC BioPharma, Inc. NASDAQ: ABVC, a clinical stage biopharmaceutical company developing therapeutic solutions in oncologyhematology, CNS, and ophthalmology, today provided an update regarding recent developments in connection with Vitargus, the worlds first bio-degradable vitreous substitute intended to facilitate retina re-attachment surgery. Early clinical studies indicate that Vitargus has unique properties that result in eliminating the need for post-surgery patient face-down positioning, as well as significantly greater recovery period patient comfort and visual acuity than currently available products. 